University of Oulu

Bur, H., Haapasaari, K-M., Turpeenniemi-Hujanen, T., Kuittinen, O., Auvinen, P., Marin, K., Soini, Y., Karihtala, P., Strong prolyl hydroxylase domain 1 expression predicts poor outcome in radiotherapy-treated patients with classical Hodgkin's lymphoma, Anticancer Research, 2018, Vol. 38:1, p. 329-336, DOI: https://doi.org/10.21873/anticanres.12226

Strong prolyl hydroxylase domain 1 expression predicts poor outcome in radiotherapy-treated patients with classical Hodgkin’s lymphoma

Saved in:
Author: Bur, Hamid1,2; Haapasaari, Kirsi-Maaria2,3; Turpeenniemi-Hujanen, Taina1,2;
Organizations: 1Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu University Hospital, Oulu, Finland
2Cancer and Translational Medicine Research Unit, University of Oulu, Oulu, Finland
3Department of Pathology, Medical Research Center Oulu, Oulu University Hospital, Oulu, Finland
4Department of Oncology, Kuopio University Hospital, Kuopio, Finland
5Cancer Center, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland
6Department of Pathology and Forensic Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland
Format: article
Version: published version
Access: open
Online Access: PDF Full Text (PDF, 0.3 MB)
Persistent link: http://urn.fi/urn:nbn:fi-fe2019110136209
Language: English
Published: International Institute of Anticancer Research, 2018
Publish Date: 2019-11-01
Description:

Abstract

Background: Hypoxia-inducible factors (HIFs) and prolyl hydroxylase domain (PHD) proteins control cellular oxygen homeostasis and a wide range of other processes.

Materials and Methods: We immunohistochemically assessed the expression of HIF1α, HIF2α, PHD1, PHD2 and PHD3 in 115 cases of classical Hodgkin’s lymphoma, all treated in the first line with doxorubicin, bleomycin, vinblastine and darcabazine (ABVD) chemotherapy.

Results: In advanced-stage patients treated with involved-field radiotherapy (IFRT), nuclear HIF1α expression in reactive cellular infiltrate predicted prolonged relapse-free survival (RFS) (p=0.026). Strong cytoplasmic PHD1 expression in Reed–Sternberg cells was associated with poor RFS among patients treated with IFRT and advanced-stage patients treated with ABVD and IFRT (p=0.0028 and p=0.0058, respectively). In Cox regression analysis, PHD1 was a more significant predictor of relapse (risk ratio=18.383; 95% confidence interval(CI)=1.521–222.246; p=0.022) than the International Prognostic Score.

Conclusion: HIF and PHD expression appear to be novel prognostic biomarkers in classical Hodgkin’s lymphoma.

see all

Series: Anticancer research
ISSN: 0250-7005
ISSN-E: 1791-7530
ISSN-L: 0250-7005
Volume: 38
Issue: 1
Pages: 329 - 336
DOI: 10.21873/anticanres.12226
OADOI: https://oadoi.org/10.21873/anticanres.12226
Type of Publication: A1 Journal article – refereed
Field of Science: 3122 Cancers
Subjects:
HIF
PHD
Funding: The Finnish Cancer Society, the Finnish Antituberculosis Association for support, Väisänen Fund in Terttu Foundation of North-Finland Healthcare Support.
Copyright information: © 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. Self-archived with the kind permission by the publisher.